IP Verse

Intas Pharmaceuticals, Ltd. et al. vs Atossa Therapeutics, Inc.

Explore the PTAB proceeding PGR2025-00043 filed by Intas Pharmaceuticals, Ltd. et al. against Atossa Therapeutics, Inc. on Apr 3, 2025. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Case Details

Proceeding Number
PGR2025-00043
Filing Date
Apr 3, 2025
Petitioner
Intas Pharmaceuticals, Ltd. et al.
Respondent
Atossa Therapeutics, Inc.
Status
Pending
Respondent Application Number
18128536
Respondent Tech Center
1600
Respondent Patent Number
12071391

Proceeding Decision New

Decision documents related to this case provide insights into the outcomes of proceedings. These documents are crucial for understanding the legal determinations and implications for the parties involved.

Document NameFiling DateCategoryFiling Party

EX2019 - Rishab Gupta & Swarndeep Singh, Endoxifen Approval for Bipolar in India, A Premature or a Pragmatic Decision?, 43(1) J. CLINICAL PSYCHOPHARMACOLOGY 3 (2023)

Jul 7, 2025EXHIBITPATENT OWNER

Proceeding Documents

The table below shows documents filed in the case, listing each document name, filing date, document type, and filing party. Tracking these filings indicates the activity of the parties involved in the case, and the types of documents filed can provide insights into the legal strategies being employed.


Document NameFiling DateCategoryFiling Party

Alert me when new update on this case

Email Correspondence

Aug 22, 2025EXHIBITBOARD

Petitioner's Response to Patent Owner's Request for Discretionary Denial of Institution

Aug 7, 2025PAPERPETITIONER

Chen P. et al. (2018)

Aug 7, 2025EXHIBITPETITIONER

Goetz MP et al. (2017)

Aug 7, 2025EXHIBITPETITIONER

Takebe N et al. (2021)

Aug 7, 2025EXHIBITPETITIONER

Patent Owner's Preliminary Response

Aug 5, 2025PAPERPATENT OWNER

EX2001 - ATOSSA THERAPEUTICS, INC. QUARTERLY REPORT FORM 10-Q for the Quarterly Period Ended March 31, 2025

Jul 7, 2025EXHIBITPATENT OWNER

EX2002 - Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025 (April 29, 2025)

Jul 7, 2025EXHIBITPATENT OWNER

EX2003 - Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications (March 11, 2025)

Jul 7, 2025EXHIBITPATENT OWNER

EX2004 - Financials – Intas Pharmaceuticals Ltd.

Jul 7, 2025EXHIBITPATENT OWNER

EX2005 - Atossa Therapeutics Announces Issuance of Key U.S. Patent Covering Endoxifen (March 8, 2022)

Jul 7, 2025EXHIBITPATENT OWNER

EX2006 - Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients, NCT06608641 (Last Updated March 17, 2025)

Jul 7, 2025EXHIBITPATENT OWNER

EX2008 - Atossa Covenant Not to Sue

Jul 7, 2025EXHIBITPATENT OWNER

EX2009 - Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density (Dec. 11, 2024)

Jul 7, 2025EXHIBITPATENT OWNER

EX2010 - Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update (May 13, 2025)

Jul 7, 2025EXHIBITPATENT OWNER

EX2012 - Breast Center Year in Review, An Unmet Need in HR-Positive Endocrine-Resistant Breast Cancer

Jul 7, 2025EXHIBITPATENT OWNER

EX2013 - ATOSSA THERAPEUTICS, INC. ANNUAL REPORT FORM 10-K for the Fiscal Year Ended December 31, 2024

Jul 7, 2025EXHIBITPATENT OWNER

EX2015 - Intas Requirements For Resolving Disputes With Atossa (FILED UNDER SEAL)

Jul 7, 2025EXHIBITPATENT OWNER

EX2016 - Default Protective Order

Jul 7, 2025EXHIBITPATENT OWNER

EX2017 - Intas Pharmaceuticals, Limited v. Atossa Therapeutics, Inc., IPR2025-00799, Pap.2 (Apr. 3, 2025)

Jul 7, 2025EXHIBITPATENT OWNER

EX2018 - Intas Pharmaceuticals, Limited v. Atossa Therapeutics, Inc., PGR2023-00043, Pap.1 (Aug. 18, 2023)

Jul 7, 2025EXHIBITPATENT OWNER

EX2019 - Rishab Gupta & Swarndeep Singh, Endoxifen Approval for Bipolar in India, A Premature or a Pragmatic Decision?, 43(1) J. CLINICAL PSYCHOPHARMACOLOGY 3 (2023)

Jul 7, 2025EXHIBITPATENT OWNER

EX2020 - Zonalta, Why Zonalta?

Jul 7, 2025EXHIBITPATENT OWNER

EX2021 - Atossa Therapeutics Granted Additional Patent Protection for Endoxifen (August 28, 2024)

Jul 7, 2025EXHIBITPATENT OWNER

EX2022 - Declaration of Megan Raymond

Jul 7, 2025EXHIBITPATENT OWNER

EX2007 - Declaration of Sayem Osman

Jul 7, 2025EXHIBITPATENT OWNER

EX2014 - U.S. Patent No. 11,572,334

Jul 7, 2025EXHIBITPATENT OWNER

Patent Owner's Motion to Seal

Jul 7, 2025PAPERPATENT OWNER

Patent Owner's Discretionary Denial Request [FILED UNDER SEAL]

Jul 7, 2025PAPERPATENT OWNER

Patent Owner's Discretionary Denial Request [REDACTED]

Jul 7, 2025PAPERPATENT OWNER

Notice: Notice filing date accorded

May 5, 2025PAPERBOARD

Power of Attorney and Designation of Lead Back-Up Counsel

Apr 17, 2025PAPERPATENT OWNER

Patent Owner's Mandatory Notices

Apr 17, 2025PAPERPATENT OWNER

USPN 12,071,391

Apr 3, 2025EXHIBITPETITIONER

File history of USPN 12,071,391

Apr 3, 2025EXHIBITPETITIONER

9,333,190 (Ahmad)

Apr 3, 2025EXHIBITPETITIONER

WO2017/70651 (Liu)

Apr 3, 2025EXHIBITPETITIONER

Excerpt of Handbook of Pharmaceutical Salts

Apr 3, 2025EXHIBITPETITIONER

Benameur

Apr 3, 2025EXHIBITPETITIONER

de Villiers

Apr 3, 2025EXHIBITPETITIONER

Stegemann

Apr 3, 2025EXHIBITPETITIONER

Excerpts of Handbook of Pharmaceutical Excipients

Apr 3, 2025EXHIBITPETITIONER

Cole

Apr 3, 2025EXHIBITPETITIONER

Ahmad (2010)

Apr 3, 2025EXHIBITPETITIONER

Ahmad (2012)

Apr 3, 2025EXHIBITPETITIONER

Fauq (2010)

Apr 3, 2025EXHIBITPETITIONER

Milroy

Apr 3, 2025EXHIBITPETITIONER

Krahn

Apr 3, 2025EXHIBITPETITIONER

A Focus on Crystallography

Apr 3, 2025EXHIBITPETITIONER

Fan

Apr 3, 2025EXHIBITPETITIONER

Urso

Apr 3, 2025EXHIBITPETITIONER

Endoxifen

Apr 3, 2025EXHIBITPETITIONER

Ansel - capsules

Apr 3, 2025EXHIBITPETITIONER

Beasley

Apr 3, 2025EXHIBITPETITIONER

WO2011/107855 (Gandhi)

Apr 3, 2025EXHIBITPETITIONER

11,572,334

Apr 3, 2025EXHIBITPETITIONER

Supporting Information to Milroy

Apr 3, 2025EXHIBITPETITIONER

Ali

Apr 3, 2025EXHIBITPETITIONER

Supporting Information to Fauq

Apr 3, 2025EXHIBITPETITIONER

Elkins

Apr 3, 2025EXHIBITPETITIONER

Reid

Apr 3, 2025EXHIBITPETITIONER

Shargel

Apr 3, 2025EXHIBITPETITIONER

Ansel

Apr 3, 2025EXHIBITPETITIONER

Wieckhusen

Apr 3, 2025EXHIBITPETITIONER

Richardson

Apr 3, 2025EXHIBITPETITIONER

Expert Declaration of Jason McConville, Ph.D.

Apr 3, 2025EXHIBITPETITIONER

Expert Declaration of Ron Bihovsky, Ph.D.

Apr 3, 2025EXHIBITPETITIONER

Notice: Power of Attorney

Apr 3, 2025PAPERPETITIONER

Petition: as filed

Apr 3, 2025PAPERPETITIONER